Marcelle Pick discusses how GLP‑1 medications (e.g., Ozempic/semaglutides) have reframed obesity by highlighting how food cravings and difficulty stopping eating drive overeating. She acknowledges the usefulness of these drugs but urges exploring alternative, potentially cost-effective approaches and warns that long‑term effects in non‑diabetic users remain unknown.
And I am grateful that the drugs are out there. I really am, because it's taught us about obesity in a different way. And what it's telling us is that so many people have the noise of food that they're really having cravings, or they don't know when to stop. They're eating a meal. But I think there's other alternatives that we can use that might be as effective. But it really helps us understand that we do need to do something about that so that people can follow a plan long term and not spend the enormous amounts of money that they are making medications. And many people are now wanting to continue after they've lost the weight loss. And again, what I reiterate is we do not know the long term effects. You know, five years down the road, if you're not diabetic and you're using these medications.
